Innocan Pharma Invites Investors to ThinkEquity Conference
HERZLIYA, Israel and Calgary, AB – Innocan Pharma Corporation (CSE: INNPF), known for its groundbreaking work in chronic pain management using Liposomal CBD drug products, is set to present significant updates at the upcoming ThinkEquity 2024 Investor Conference. This highly anticipated event will take place at the Mandarin Oriental Hotel, offering a prime opportunity for Innocan to showcase its achievements to a diverse audience.
Key Presentation Details
During the conference, Innocan Pharma will outline its recent regulatory successes, particularly its approval for a 505(2)(b) abbreviated pathway from the U.S. Food and Drug Administration (FDA) for its human health applications. Notably, this includes a sponsor fee waiver and an Investigational New Animal Drug number (INAD) from the FDA Center for Veterinary Medicine for animal health applications.
Iris Bincovich, the CEO of Innocan, will take the stage on the conference day, providing insights on the company’s path forward. Prospective investors and stakeholders are encouraged to engage in one-on-one meetings with the executive team to discuss opportunities and collaborations.
Conference Participation Opportunities
Attendees can look forward to an event featuring over 75 companies from various sectors, including technology and biotechnology. The format provides half-hour increments for presentations, alongside opportunities for meaningful interactions with institutional investors, family offices, and leading industry executives. This network-rich environment is perfect for Innocan to establish and strengthen valuable connections.
Website Relaunch Enhances Investor Communication
In addition to participating in the conference, Innocan Pharma is excited to announce the relaunch of its website, designed to enrich the experience for investors and partners. The updated design offers a more intuitive layout, allowing easier access for collaborators, pharmaceutical companies, and investors to stay informed about Innocan's strategic developments and milestones.
About Innocan Pharma
Innocan Pharma stands at the forefront of innovation within the pharmaceutical and wellness industries. The company has introduced a CBD-loaded liposome drug delivery platform, tailored for precise dosing and controlled release of synthetic CBD, providing a non-opioid solution for pain management. Furthermore, Innocan is committed to wellness through a broad range of high-performance self-care and beauty products, aiming to promote healthier lifestyles.
Company Contact
For further inquiries regarding Innocan Pharma Corporation, interested parties can reach out to Iris Bincovich, CEO, at the following contact numbers:
- +1 5162104025
- +972-54-3012842
- +442037699377
Frequently Asked Questions
What is Innocan Pharma's core focus?
Innocan Pharma focuses on developing innovative CBD drug products for chronic pain management and wellness solutions.
Who is presenting at the ThinkEquity 2024 conference?
Iris Bincovich, the CEO of Innocan Pharma, will be presenting at the conference.
What recent achievements will Innocan discuss?
Innocan will discuss its regulatory milestones, including FDA approvals for its human and animal health applications.
How can investors engage with Innocan at the conference?
Investors can schedule one-on-one meetings with Innocan's executive team during the conference.
What improvements were made to Innocan's website?
The revamped website features a streamlined interface for better access to key information and updates for investors and partners.
